logo
  

University Of Tokyo, Astellas Pharma Enter Second Phase Of Collaboration - Quick Facts

Astellas Pharma Inc. (ALPMY,ALPMY) announced the company and the University of Tokyo have entered the second phase of collaboration for co-creating new medicines and medical solutions, called the Astellas Alliance Acceleration Program. The University of Tokyo will expand its partnership involvement to include all of its institutions. A newly appointed AAAP-dedicated project manager will be stationed at the university to facilitate the collaboration.

Yoshitsugu Shitaka, Chief Scientific Officer at Astellas, said: "By leveraging the power of the more extensive and closer collaboration, we expect to accelerate the co-creation of innovations that contribute to our activities from early drug discovery research to clinical development."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. may face production shortfall of as many as 6 million iPhone Pro units this year due to ongoing protests at its major China plant, Bloomberg reported citing a person familiar with assembly operations. Following the news, Apple shares were losing around 2.2 percent in pre-market activity on the Nasdaq. Despite fears of inflation, consumers spent $9.12 billion for online shopping during Black Friday, higher than in previous years, as per a report published by Adobe Analytics. During the 2022 holiday season, total estimated revenues are $209.7 billion, a growth of 2.5 percent from last year's recorded revenues of $205 billion. Weis Markets, Inc., a Mid Atlantic food retailer, has recalled 108 containers of Weis Quality Sea Salt Caramel Ripple Ice Cream citing possible presence of undeclared soy and coconut allergens, the U.S. Food and Drug Administration said. The recalled product comes in 48oz containers that says Weis Quality Sea Salt Caramel Ripple Ice Cream, while the lid says Weis Quality Caramel Caribou Ice Cream
Follow RTT